Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
Gamida Cell Ltd. - Ordinary Shares (GMDA)
Last gamida cell ltd. - ordinary shares earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
– Topline data expected in first half of 2020 – BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 study of the company’s lead clinical program, omidubicel, an investigational advanced cell therapy being evaluated as a potential life-saving treatment option for patients with high-risk hematologic malignancies who are in need of a bone marrow transplant. Topline data from the study are expected in the first half of 2020.“Completing patient recruitment for the Phase 3 study of omidubicel is a very significant milestone for our company,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. “Positive data would enable us to file our first biologics license application in the second half of 2020 and would represent an important step toward becoming a fully integrated company that
Show less
Read more
Impact Snapshot
Event Time:
GMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMDA alerts
High impacting Gamida Cell Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GMDA
News
- Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewswire
- GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer [Yahoo! Finance]Yahoo! Finance
- Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR® [Yahoo! Finance]Yahoo! Finance
- Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®GlobeNewswire
GMDA
Earnings
- 11/14/23 - Beat
GMDA
Sec Filings
- 4/5/24 - Form 8-K/A
- 4/1/24 - Form SC
- 3/29/24 - Form 8-K/A
- GMDA's page on the SEC website